<DOC>
	<DOCNO>NCT00048412</DOCNO>
	<brief_summary>1 . To assess treatment related mortality allogeneic stem cell transplantation non-myeloablative therapy incorporate lymphodepleting MAb CAMPATH-1H , patient hematological disease renal cell carcinoma eligible conventional ( myeloablative ) therapy . 2 . To assess time engraftment incidence graft failure patient receive transplant regimen . 3 . To assess safety , pharmacokinetics immunologic activity CAMPATH-1H use part subablative conditioning regimen .</brief_summary>
	<brief_title>Stem Cell Transplant Patients With Blood Malignancy Using Donors Less Toxic Chemotherapy With CAMPATH 1H</brief_title>
	<detailed_description>This two arm study outcome assess independently recipient HLA match sibling transplant recipient unrelated mismatch family donor transplant , although group receive identical treatment . The follow give patient admission : Day - 6 : Total body irradiation Day - 5 - 2 : Fludarabine Campath 1H Day - 1 : Day rest Day 0 : Stem cell transplant ( infusion )</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion criterion 1 . Diagnosis myelodysplastic disorder , Acute Myelogenous Leukemia , Acute Lymphoblastic Leukemia , Multiple Myeloma , Plasma Cell Dyscrasia , Lymphoproliferative disorder ( NonHodgkin Lymphoma , Hairy Cell Leukemia , Chronic Lymphocytic Leukemia Hodgkins Disease ) Renal Cell Carcinoma . 2 . Conditions increase treatment related mortality ( need one eligible ) : 1 . Greater equal 50 year age . 2 . EF le 45 % 3 . DLCO le 50 % FEV1 5075 % predict value . 4 . Diabetes Mellitus 5 . Renal Insufficiency ( creatine clearance le 25ml/min ) . 6 . Prior recent history systemic fungal infection . 7 . 3rd great remission AML ALL 8 . More 1 year diagnosis ( CML Myeloma patient ) 9 . Multiple type treatment regimen . ( equal 3 ) 10 . Prior autologous allogeneic stem cell transplantation . 11 . Significant grade III IV neurologic hepatic toxicity previous treatment . 12 . No matched sibling donor . 3 . Available healthy donor without contraindication donation . 5/6 6/6 related donor . 5/6 6/6 unrelated donor ( molecular type DRB1 ) 4 . Patient and/or responsible person able understand consent . 5 . Age birth 70 year . 6 . For woman childbearing potential , negative pregnancy test . Exclusion criteria 1 . Patient pregnant , lactate unwilling use contraceptives 2 . HIV positive patient 3 . Uncontrolled intercurrent infection 4 . Refractory AML , ALL 5 . Untreated Blast Crisis CML 6 . Uncontrolled Highgrade lymphoproliferative disease/lymphoma . 7 . Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) 8 . Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) 9 . Hemodialysis dependent 10 . Active Hepatitis cirrhosis total bilirubin , SGOT , SGPT great 3 x normal . 11 . Unstable Cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) 12 . Active CNS disease hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>